Durvalumab-associated generalized morphea with overlapping vitiligo

Julianna Martel; Woo Cheal Cho; John S Runge; Anisha B Patel; Jean Tayar; Karin Woodman; Celyne Bueno Hume; Jonathan Curry; Meghan Heberton

doi:10.1016/j.jdcr.2022.10.007

Durvalumab-associated generalized morphea with overlapping vitiligo

JAAD Case Rep. 2022 Oct 13:30:83-86. doi: 10.1016/j.jdcr.2022.10.007. eCollection 2022 Dec.

Authors

Julianna Martel¹, Woo Cheal Cho², John S Runge³, Anisha B Patel^{1

4}, Jean Tayar⁵, Karin Woodman⁶, Celyne Bueno Hume⁷, Jonathan Curry^{2

8}, Meghan Heberton⁹

Affiliations

¹ Department of Dermatology, University of Texas Medical School at Houston, Houston, Texas.
² Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
³ University of Michigan Medical School, Ann Arbor, Missouri.
⁴ Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
⁵ Department of Rheumatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
⁶ Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
⁷ Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
⁸ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
⁹ Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas.

No abstract available

Keywords: PD-L1; PD-L1, programmed cell death receptor ligand 1; durvalumab; immunotherapy; irAEs, immune-related adverse events; morphea; vitiligo.

Publication types

Case Reports